Serum Levels of Cyfra 21 in Patients with Benign and Malignant Salivary Gland Tumors
Authors
Abstract:
Introduction: Cyfra 21 is a serum-soluble fragment of cytokeratin19. Increased Cyfra 21 serum levels and their benefit as a tumor marker have been shown in some malignancies. This study aimed to evaluate the serum levels of Cyfra 21 in patients with benign and malignant salivary gland tumors. Materials and Methods: In this cross-sectional study, the serum level of Cyfra 21 in 44 patients with malignant salivary gland tumors and 16 cases of pleomorphic adenoma were compared with 28 healthy controls using enzyme-linked immunosorbent assay (ELISA). Data were analyzed statistically using the Kruskal Wallis test, analysis of variance (ANOVA) and Spearman’s correlation tests. Results: Mean serum levels of Cyfra 21 were 0.135 ± 0.285 ng/ ml in the control group, 0.167 ± 0.142 ng/ ml in patients with pleomorphic adenoma and 1.059 ± 3.251 ng/ml in patients with malignant salivary gland tumors. There was no significant difference among groups. Cyfra 21 levels did not correlate with location of tumor, clinical stage or cigarette smoking. Conclusion: Results of the present study showed no significant difference in Cyfra 21 serum level in salivary gland tumors compared with normal individuals. In addition, Cyfra 21 serum level was not sufficiently sensitive to function as a tumor marker in salivary gland tumors.
similar resources
MTA1 Expression in Benign and Malignant Salivary gland Tumors
Introduction: Salivary gland tumors (SGTs) are important parts of human neoplasms. The most common SGT is pleomorphic adenoma and the most common malignant SGTs are mucoepidermoid carcinoma and adenoid cystic carcinoma (ACC). Metastasis-associated genes 1 (MTA1), a member of the nucleosome remodeling and histone deacetylation complex, is one newly discovered gene which recruits histone deacetyl...
full textNeoangiogenesis in Benign and Malignant Salivary Gland Tumors
Introduction: There are few studies investigating the role of neoangiogenesis in biological behavior of salivary gland tumors. CD105 expression has demonstrated greater accuracy for detecting new vessel formation compared with other pan-endothelial molecules. This study aimed to assess and compare intratumoral Micro-Vessel Density (MVD) through using immunohistochemichal expression of CD105 bio...
full textT-helper Type 1 and 2 Cytokine Levels in Patients with Benign and Malignant Salivary Gland Tumors
Background: Salivary gland tumors are among malignancies that have high recurrence rate. Immune responses in salivary gland tumors have not been well elucidated. T helper type 1 (Th1) and Th2 cytokines have been reported to play a role in the outcome of head and neck cancers. Objective: To evaluate the serum levels of interferon gamma (IFN- γ), as the hallmark of Th1 cytokines, and interleukin-...
full textGSK3β and CREB3 Gene Expression Profiling in Benign and Malignant Salivary Gland Tumors
Background: Salivary gland tumors (SGT) are rare lesions with uncertain histopathology. One of the major signaling pathways that participate in the development of several tumors is protein kinase A. In this pathway, glycogen synthase kinase β (GSK3β) and cAMP responsive element binding protein (CREB3) are two genes which are supposed to be down regulated in most human tumors. The expression lev...
full textmta1 expression in benign and malignant salivary gland tumors
introduction: salivary gland tumors (sgts) are important parts of human neoplasms. the most common sgt is pleomorphic adenoma and the most common malignant sgts are mucoepidermoid carcinoma and adenoid cystic carcinoma (acc). metastasis-associated genes 1 (mta1), a member of the nucleosome remodeling and histone deacetylation complex, is one newly discovered gene which recruits histone deacetyl...
full textMy Resources
Journal title
volume 29 issue 4
pages 203- 208
publication date 2017-07-01
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023